Shi-jiang
President & CEO
VcanBio Center for Translational Biotechnology
China
Biography
Shi-Jiang (John) Lu is currently the President and CEO of VcanBio CTB. and HebeCell Corporation. Before joining VcanBio Center for Translational Biotechnology and HebeCell, John was the Senior Director of Research at Ocata Therapeutics, which was recently acquired by Astellas, the 2nd largest pharmaceutical company of Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. John has been conducting translational researches and novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. The goal of his research is to generate hESC/iPSC-derived products for the treatment of human diseases. He has extensive experience in process development and large-scale production of human pluripotent stem cell derivatives for clinical applications.John received his Ph.D degree in Oncology and Cancer Biology from University of Toronto/Ontario Cancer Institute, an M.P.H degree from Columbia University, an M.S. degree in Oncology from Peking Union Medical College and a B.S. degree in Biochemistry from Wuhan University.
Research Interest
Cancer biology, Oncology, Biochemistry.
